UA70319C2 - Combination of levodopa and riluzole for treating combination of levodopa and riluzole for treating parkinson disease parkinson disease - Google Patents

Combination of levodopa and riluzole for treating combination of levodopa and riluzole for treating parkinson disease parkinson disease Download PDF

Info

Publication number: UA70319C2
Authority: UA; Ukraine
Prior art keywords: riluzole; dof; combination; combination according; levodopa
Prior art date: 1998-04-24

Application number

UA2000105983A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Aventis Pharma S A Aventis Pha

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-24

Filing date

1999-04-22

Publication date

2004-10-15

1999-04-22 Application filed by Aventis Pharma S A Aventis Pha filed Critical Aventis Pharma S A Aventis Pha

2004-10-15 Publication of UA70319C2 publication Critical patent/UA70319C2/uk

Links

FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title claims abstract description 29
229960004181 riluzole Drugs 0.000 title claims abstract description 28
208000018737 Parkinson disease Diseases 0.000 title claims abstract description 8
229960004502 levodopa Drugs 0.000 title abstract description 10
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract description 4
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract description 4
150000003839 salts Chemical class 0.000 claims abstract description 8
239000003954 decarboxylase inhibitor Substances 0.000 claims description 14
229940123736 Decarboxylase inhibitor Drugs 0.000 claims description 13
208000012661 Dyskinesia Diseases 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 2
230000037023 motor activity Effects 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
208000027089 Parkinsonian disease Diseases 0.000 description 11
206010034010 Parkinsonism Diseases 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 9
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
230000002354 daily effect Effects 0.000 description 7
230000000694 effects Effects 0.000 description 7
241001515942 marmosets Species 0.000 description 6
239000000243 solution Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229960003638 dopamine Drugs 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
210000005064 dopaminergic neuron Anatomy 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
102000004031 Carboxy-Lyases Human genes 0.000 description 2
108090000489 Carboxy-Lyases Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
230000006742 locomotor activity Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000003523 substantia nigra Anatomy 0.000 description 2
239000000725 suspension Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
238000009736 wetting Methods 0.000 description 2
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
206010006100 Bradykinesia Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
241000764773 Inna Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
241000159610 Roya <green alga> Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
VYEYJCBEXFTGBN-UHFFFAOYSA-N acetic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 VYEYJCBEXFTGBN-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000021022 fresh fruits Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000002966 varnish Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
External Artificial Organs (AREA)

UA2000105983A 1998-04-24 1999-04-22 Combination of levodopa and riluzole for treating combination of levodopa and riluzole for treating parkinson disease parkinson disease UA70319C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9805153A FR2777781B1 (fr)	1998-04-24	1998-04-24	Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
PCT/FR1999/000953 WO1999055336A1 (fr)	1998-04-24	1999-04-22	Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson

Publications (1)

Publication Number	Publication Date
UA70319C2 true UA70319C2 (en)	2004-10-15

Family

ID=9525640

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000105983A UA70319C2 (en)	1998-04-24	1999-04-22	Combination of levodopa and riluzole for treating combination of levodopa and riluzole for treating parkinson disease parkinson disease

Country Status (22)

Country	Link
US (1)	US6387936B1 (cs)
EP (1)	EP1071422B1 (cs)
JP (1)	JP2002512963A (cs)
KR (1)	KR100597170B1 (cs)
AT (1)	ATE386520T1 (cs)
AU (1)	AU768069B2 (cs)
CA (1)	CA2329636C (cs)
CY (1)	CY1110448T1 (cs)
CZ (1)	CZ300825B6 (cs)
DE (1)	DE69938179T2 (cs)
DK (1)	DK1071422T3 (cs)
ES (1)	ES2300141T3 (cs)
FR (1)	FR2777781B1 (cs)
HU (1)	HU228902B1 (cs)
IL (1)	IL139164A (cs)
NO (1)	NO329032B1 (cs)
PT (1)	PT1071422E (cs)
RU (1)	RU2225204C2 (cs)
SK (1)	SK285531B6 (cs)
UA (1)	UA70319C2 (cs)
WO (1)	WO1999055336A1 (cs)
ZA (1)	ZA200005758B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2786101B1 (fr) *	1998-11-24	2002-07-05	Aventis Laboratoire	Utilisation de la nicergoline dans le traitement de la spasticite
US6872739B1 (en)	1999-06-04	2005-03-29	Vereniging Voor Christelijk Wetenshappelikjk Onderwijs	Use of riluzole for the treatment of multiple sclerosis
GB0007193D0 (en) *	2000-03-25	2000-05-17	Univ Manchester	Treatment of movrmrnt disorders
US8158149B2 (en) *	2004-05-12	2012-04-17	Chelsea Therapeutics, Inc.	Threo-DOPS controlled release formulation
WO2004100929A1 (en)	2003-05-12	2004-11-25	Synergia Pharma, Inc.	Threo-dops controlled release formulation
WO2005025561A1 (en) *	2003-09-04	2005-03-24	Synergia Pharma, Inc.	Compositions and methods for orthostatic intolerance
EP1746985A4 (en) *	2004-05-21	2010-08-11	Univ Duke	METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS
SE0401842D0 (sv)	2004-07-12	2004-07-12	Dizlin Medical Design Ab	Infusion and injection solution of levodopa
PL1817006T3 (pl) *	2004-11-07	2013-03-29	F Timothy Guilford	Liposomalny preparat do doustnego podawania glutationu (zredukowanego)
GB0504103D0 (en) *	2005-02-28	2005-04-06	Syngenta Ltd	Novel method
AU2006261893A1 (en) *	2005-06-23	2007-01-04	Combinatorx, Incorporated	Improved dosage forms for movement disorder treatment
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
EP2363124B1 (en) *	2006-06-28	2016-02-17	Lundbeck NA Ltd	Pharmaceutical compositions comprising droxidopa
WO2008079404A2 (en) *	2006-12-22	2008-07-03	Combinatorx, Incorporated	Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008226541B2 (en) *	2007-03-09	2013-05-09	Chelsea Therapeutics, Inc.	Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2514417A3 (en) *	2007-05-07	2013-01-30	Chelsea Therapeutics, Inc.	Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
MX2010014222A (es) *	2008-06-30	2011-03-29	Novartis Ag Star	Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
US20100160295A1 (en) *	2008-11-06	2010-06-24	Synosia Therapeutics	Treatment of restless leg syndrome and sleep disorders
EP2228054A1 (en) *	2009-03-13	2010-09-15	ITALFARMACO S.p.A.	Riluzole aqueous suspensions
EP2629615B1 (en)	2010-10-22	2018-10-10	Duke University	Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
JP5880913B2 (ja)	2011-05-17	2016-03-09	三郎佐古田	パーキンソン病の体幹症状（姿勢反射異常）の治療剤
WO2014172372A1 (en)	2013-04-15	2014-10-23	Northwestern University	Treatment for dopaminergic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2700117B1 (fr) *	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU2057529C1 (ru) *	1994-05-30	1996-04-10	Алексей Михайлович Коршунов	Способ лечения синдрома паркинсонизма

1998
- 1998-04-24 FR FR9805153A patent/FR2777781B1/fr not_active Expired - Fee Related
1999
- 1999-04-22 HU HU0101645A patent/HU228902B1/hu not_active IP Right Cessation
- 1999-04-22 AT AT99915809T patent/ATE386520T1/de active
- 1999-04-22 DK DK99915809T patent/DK1071422T3/da active
- 1999-04-22 DE DE69938179T patent/DE69938179T2/de not_active Expired - Lifetime
- 1999-04-22 WO PCT/FR1999/000953 patent/WO1999055336A1/fr not_active Ceased
- 1999-04-22 IL IL13916499A patent/IL139164A/xx not_active IP Right Cessation
- 1999-04-22 UA UA2000105983A patent/UA70319C2/uk unknown
- 1999-04-22 CZ CZ20003908A patent/CZ300825B6/cs not_active IP Right Cessation
- 1999-04-22 CA CA002329636A patent/CA2329636C/fr not_active Expired - Fee Related
- 1999-04-22 AU AU34255/99A patent/AU768069B2/en not_active Ceased
- 1999-04-22 SK SK1588-2000A patent/SK285531B6/sk not_active IP Right Cessation
- 1999-04-22 KR KR1020007011786A patent/KR100597170B1/ko not_active Expired - Fee Related
- 1999-04-22 JP JP2000545534A patent/JP2002512963A/ja not_active Withdrawn
- 1999-04-22 ES ES99915809T patent/ES2300141T3/es not_active Expired - Lifetime
- 1999-04-22 EP EP99915809A patent/EP1071422B1/fr not_active Expired - Lifetime
- 1999-04-22 PT PT99915809T patent/PT1071422E/pt unknown
- 1999-04-22 RU RU2000129121/15A patent/RU2225204C2/ru not_active IP Right Cessation
2000
- 2000-10-17 ZA ZA200005758A patent/ZA200005758B/en unknown
- 2000-10-20 NO NO20005290A patent/NO329032B1/no not_active IP Right Cessation
- 2000-10-24 US US09/694,860 patent/US6387936B1/en not_active Expired - Lifetime
2008
- 2008-04-24 CY CY20081100457T patent/CY1110448T1/el unknown

Also Published As

Publication number	Publication date
DE69938179T2 (de)	2009-02-12
US6387936B1 (en)	2002-05-14
CZ20003908A3 (cs)	2001-02-14
ZA200005758B (en)	2002-01-17
PT1071422E (pt)	2008-05-05
JP2002512963A (ja)	2002-05-08
SK285531B6 (sk)	2007-03-01
CA2329636C (fr)	2009-09-08
CA2329636A1 (fr)	1999-11-04
FR2777781A1 (fr)	1999-10-29
NO20005290D0 (no)	2000-10-20
NO20005290L (no)	2000-10-20
CY1110448T1 (el)	2015-04-29
IL139164A0 (en)	2001-11-25
AU3425599A (en)	1999-11-16
DE69938179D1 (de)	2008-04-03
KR100597170B1 (ko)	2006-07-05
NO329032B1 (no)	2010-08-02
WO1999055336A1 (fr)	1999-11-04
ATE386520T1 (de)	2008-03-15
RU2225204C2 (ru)	2004-03-10
KR20010042960A (ko)	2001-05-25
DK1071422T3 (da)	2008-06-16
SK15882000A3 (sk)	2001-04-09
HUP0101645A2 (hu)	2001-09-28
EP1071422A1 (fr)	2001-01-31
HUP0101645A3 (en)	2002-10-28
AU768069B2 (en)	2003-12-04
ES2300141T3 (es)	2008-06-01
FR2777781B1 (fr)	2004-04-09
EP1071422B1 (fr)	2008-02-20
HU228902B1 (en)	2013-06-28
IL139164A (en)	2005-12-18
CZ300825B6 (cs)	2009-08-19

Publication	Publication Date	Title
RU2225204C2 (ru)	2004-03-10	Комбинации рилузола с l-дофа для лечения болезни паркинсона
US10022386B2 (en)	2018-07-17	Tomatidine, analogs thereof, compositions comprising same, and uses for same
Meng et al.	2011	AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway
EP2983661B1 (en)	2024-05-29	Formulations of oxabicycloheptanes and oxabicycloheptenes
WO2002038153A1 (en)	2002-05-16	New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
KR20190111133A (ko)	2019-10-01	전립선암 치료용 조합, 약학 조성물 및 치료 방법
CZ288063B6 (cs)	2001-04-11	Farmaceutický prostředek pro léčení rakovin
EP2117306A2 (en)	2009-11-18	Neurogenic compounds
CA1278519C (en)	1991-01-02	Dementia-improving and therapeutic agents
MX2008016125A (es)	2009-01-15	Compuestos organicos.
US4291030A (en)	1981-09-22	Method of lowering blood cholesterol
US8809303B2 (en)	2014-08-19	Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
Skinner et al.	2018	Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™(New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments
JPS58174313A (ja)	1983-10-13	動物組織の線維化抑制剤
EP0137514B1 (en)	1988-09-21	Compounds and compositions for use in preventing and treating obesity
JP7144052B2 (ja)	2022-09-29	掻痒性皮膚疾患の予防又は治療薬
US2967130A (en)	1961-01-03	p-sulfamyl beta-hydroxyethyl carbanilate diuretic compositions
US3296074A (en)	1967-01-03	Methods and compositions for treating psychoses and neuroses
EP3278802A1 (en)	2018-02-07	New treatment for the non alcoholic steatohepatitis and fibrosis
CN105037354A (zh)	2015-11-11	一种吡嗪异喹啉衍生物在制备治疗血吸虫药物中的应用
Anadón et al.	1989	Effect of tiamulin on antipyrine kinetics in chickens
RU2858534C1 (ru)	2026-03-18	4,10-диморфолинацетил-2,6,8,12-тетраацетил-2,4,6,8,10,12-гексаазаизовюрцитан в качестве анксиолитического средства и способ его получения
Doisy Jr et al.	1950	Inositol and the Toxicity of Four Isomers of Benzenehexachloride for the Rat
US20240000831A1 (en)	2024-01-04	Molecular basis of fatty liver inhibition by sodium borates
Chakravarti et al.	1958	Experimental urolithiasis in rat with foreign body in the bladder and role of infection in its production